138 related articles for article (PubMed ID: 23373656)
1. Exploiting protein phosphatase inhibitors based on cantharidin analogues for cancer drug discovery.
Deng L; Dong J; Wang W
Mini Rev Med Chem; 2013 Jun; 13(8):1166-76. PubMed ID: 23373656
[TBL] [Abstract][Full Text] [Related]
2. Norcantharidin analogues: synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition.
Hill TA; Stewart SG; Gordon CP; Ackland SP; Gilbert J; Sauer B; Sakoff JA; McCluskey A
ChemMedChem; 2008 Dec; 3(12):1878-92. PubMed ID: 19025735
[TBL] [Abstract][Full Text] [Related]
3. Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues.
Sakoff JA; Ackland SP; Baldwin ML; Keane MA; McCluskey A
Invest New Drugs; 2002 Feb; 20(1):1-11. PubMed ID: 12003183
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A.
Shan HB; Cai YC; Liu Y; Zeng WN; Chen HX; Fan BT; Liu XH; Xu ZL; Wang B; Xian LJ
Anticancer Drugs; 2006 Sep; 17(8):905-11. PubMed ID: 16940800
[TBL] [Abstract][Full Text] [Related]
5. Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A.
McCluskey A; Walkom C; Bowyer MC; Ackland SP; Gardiner E; Sakoff JA
Bioorg Med Chem Lett; 2001 Nov; 11(22):2941-6. PubMed ID: 11677131
[TBL] [Abstract][Full Text] [Related]
6. Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
Hill TA; Stewart SG; Sauer B; Gilbert J; Ackland SP; Sakoff JA; McCluskey A
Bioorg Med Chem Lett; 2007 Jun; 17(12):3392-7. PubMed ID: 17451951
[TBL] [Abstract][Full Text] [Related]
7. Optically active cantharidin analogues possessing selective inhibitory activity on Ser/Thr protein phosphatase 2B (calcineurin): implications for the binding mode.
Baba Y; Hirukawa N; Sodeoka M
Bioorg Med Chem; 2005 Sep; 13(17):5164-70. PubMed ID: 15951185
[TBL] [Abstract][Full Text] [Related]
8. Overview of Cantharidin and its Analogues.
Wang G; Dong J; Deng L
Curr Med Chem; 2018; 25(17):2034-2044. PubMed ID: 28413963
[TBL] [Abstract][Full Text] [Related]
9. Crystal structures and mutagenesis of PPP-family ser/thr protein phosphatases elucidate the selectivity of cantharidin and novel norcantharidin-based inhibitors of PP5C.
Chattopadhyay D; Swingle MR; Salter EA; Wood E; D'Arcy B; Zivanov C; Abney K; Musiyenko A; Rusin SF; Kettenbach A; Yet L; Schroeder CE; Golden JE; Dunham WH; Gingras AC; Banerjee S; Forbes D; Wierzbicki A; Honkanen RE
Biochem Pharmacol; 2016 Jun; 109():14-26. PubMed ID: 27002182
[TBL] [Abstract][Full Text] [Related]
10. Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
Ren Y; Kinghorn AD
Bioorg Med Chem; 2021 Feb; 32():116012. PubMed ID: 33454654
[TBL] [Abstract][Full Text] [Related]
11. Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines.
McCluskey A; Ackland SP; Bowyer MC; Baldwin ML; Garner J; Walkom CC; Sakoff JA
Bioorg Chem; 2003 Feb; 31(1):68-79. PubMed ID: 12697169
[TBL] [Abstract][Full Text] [Related]
12. Anhydride modified cantharidin analogues. Is ring opening important in the inhibition of protein phosphatase 2A?
McCuskey A; Keane MA; Mudgee LM; Sim AT; Sakoff J; Quinn RJ
Eur J Med Chem; 2000 Oct; 35(10):957-64. PubMed ID: 11121622
[TBL] [Abstract][Full Text] [Related]
13. A Review for Mini-Review in Medicinal Chemistry.
Deng L; Tang S; Qian Q
Mini Rev Med Chem; 2012 Apr; ():. PubMed ID: 22512589
[TBL] [Abstract][Full Text] [Related]
14. Crystal structures of protein phosphatase-1 bound to nodularin-R and tautomycin: a novel scaffold for structure-based drug design of serine/threonine phosphatase inhibitors.
Kelker MS; Page R; Peti W
J Mol Biol; 2009 Jan; 385(1):11-21. PubMed ID: 18992256
[TBL] [Abstract][Full Text] [Related]
15. The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?
McCluskey A; Ackland SP; Gardiner E; Walkom CC; Sakoff JA
Anticancer Drug Des; 2001 Dec; 16(6):291-303. PubMed ID: 12375882
[TBL] [Abstract][Full Text] [Related]
16. Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
McCluskey A; Bowyer MC; Collins E; Sim ATR ; Sakoff JA; Baldwin ML
Bioorg Med Chem Lett; 2000 Aug; 10(15):1687-90. PubMed ID: 10937725
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of serine/threonine phosphatase inhibition by the archetypal small molecules cantharidin and norcantharidin.
Bertini I; Calderone V; Fragai M; Luchinat C; Talluri E
J Med Chem; 2009 Aug; 52(15):4838-43. PubMed ID: 19601647
[TBL] [Abstract][Full Text] [Related]
18. Tautomycin's interactions with protein phosphatase 1.
Sydnes MO; Isobe M
Chem Asian J; 2010 Mar; 5(3):410-20. PubMed ID: 20013999
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of norcantharidin analogues: towards PP1 selectivity.
Stewart SG; Hill TA; Gilbert J; Ackland SP; Sakoff JA; McCluskey A
Bioorg Med Chem; 2007 Dec; 15(23):7301-10. PubMed ID: 17870547
[TBL] [Abstract][Full Text] [Related]
20. Protein phosphatase 2A and its [3H]cantharidin/[3H]endothall thioanhydride binding site. Inhibitor specificity of cantharidin and ATP analogues.
Li YM; Mackintosh C; Casida JE
Biochem Pharmacol; 1993 Oct; 46(8):1435-43. PubMed ID: 8240393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
